Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Two pivotal HZT-501 phase III trials meet primary endpoints

Dec. 4, 2008

Questcor resubmits sNDA to FDA for H.P. Acthar Gel for infantile spasms

Dec. 4, 2008

sPLA2 inhibition beneficial in animal models of spinal cord injury

Dec. 3, 2008

Recent Teva and Roche patents disclose new antipsychotic agents

Dec. 3, 2008

TorreyPines reports results from study of NGX-426 in capsaicin-induced pain

Dec. 2, 2008

Paladin and GSK sign 3-year distribution agreement for Dexedrine for ADHD

Dec. 2, 2008

Positive results reported for novel HDAC inhibitor in experimental Huntington's disease in mice

Dec. 2, 2008

Prana provides update on research and development programs

Dec. 2, 2008

Novel dual CB1/CB2 receptor agonist efficacious in experimental pain models

Dec. 2, 2008

Lilly withdraws Cymbalta sNDA, plans to resubmit in 2009 with additional data

Dec. 1, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...